ADVA
7.6.2021 09:09:59 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that its FSP 3000 open line system (OLS) and Ensemble Controller network management and SDN domain controller system played a key role in a successful Telecom Infra Project (TIP) open optical networking proof of concept (PoC). The demo is a crucial step for vendor-neutral disaggregated solutions with operators able to mix and match best-in-breed technology and leverage different product lifecycles. The PoC showed how multi-vendor network components can be managed by a unified software-defined networking (SDN) control system. Specifically designed for easy interoperability, ADVA’s FSP 3000 OLS and Ensemble Controller ensured seamless integration into the open environment, including third-party terminals. The PoC will be on display at OFC at the virtual Demo Zone from June 7 to 11.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210607005193/en/
“This PoC is an important milestone in the journey to fully open and disaggregated optical networking. It offers new levels of visibility and a way to manage the entire multi-vendor environment. With the power to seamlessly integrate components from different suppliers, network operators can confidently deploy best-in-class infrastructure that meets their exact requirements,” said Christoph Glingener, CTO, ADVA. “Our FSP 3000 OLS was central to the demo. It’s a truly open solution that gives operators freedom to build multi-supplier architectures and then evolve and optimize each network layer separately. With our Ensemble Controller also playing a major role – providing network management and programmatic SDN control – this demo highlights the value of technology like ours that supports interoperability and disaggregation.”
Conducted by TIP’s Converged Architectures for Network Disaggregation & Integration (CANDI) sub-group, the PoC proved that all components of an open optical network can be operated by a single SDN controller. By demonstrating unified management of the OLS, open terminals and optical planning tool, the demo paves the way for true open networking and a new model of infrastructure operations with operators taking over network integration and optimization processes. The demo utilized ADVA’s compact and modular FSP 3000 OLS. With its open interfaces, the OLS interworks seamlessly with third-party transceivers and supports the latest coherent transport innovation. It also featured ADVA’s Ensemble Controller network management system, which was specifically designed to help network operators break up network layers while moving towards a software-defined multi-vendor architecture. TIP partners collaborating with ADVA on the demo included the major network operators Orange, Telefónica and Telia Company.
“The success of TIP’s PoC offers a major boost to communication service providers looking to harness the benefits of increased agility and supplier diversity in their optical infrastructure. Our open technology gives network operators the opportunity to massively increase efficiencies by moving away from closed proprietary systems and towards vendor-neutral networking,” commented Stephan Neidlinger, VP, global business development, ADVA. “The TIP community has once again accomplished a significant step forward for open, disaggregated and standards-based connectivity technology. By collaborating closely with our partners in this project, our team has helped to accelerate the development of the next generation of communication networks, free from vendor lock-in and ready to connect tomorrow’s world.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
View source version on businesswire.com: https://www.businesswire.com/news/home/20210607005193/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
